E-MTAB-8408
Ontology highlight
ABSTRACT:
PROVIDER: E-MTAB-8408 | ExpressionAtlas | 2020-01-13
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-MTAB-8408-analysis-methods.tsv | Tabular | |||
| E-MTAB-8408-analytics.tsv | Tabular | |||
| E-MTAB-8408-atlasExperimentSummary.Rdata | Rdata | |||
| E-MTAB-8408-configuration.xml | Xml | |||
| E-MTAB-8408-g1_g2-mvaPlot.png | Other |
Items per page: 5 1 - 5 of 22 |
Similar Datasets
Project description:Current cancer immunotherapies are assumed to improve infiltration and cytotoxicity of immune cells in the tumor. However, tumor cells have developed a variety of resistance mechanisms to suppress the MHC class I antigen presentation, and thereby impair the cytotoxicity of CD8+ T cells. Here, we identified Mal2 as a key player that mediates the turnover of the antigen-MHC-I complex and reduce the antigen presentation on tumor cells. Mal2 promotes the endocytosis of tumor antigen via direct interaction with the MHC-I complex and endosome-associated Rab5/7. In mouse and human breast tumor models, inhibition of Mal2 profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that Mal2 is a potential target for breast cancer immunotherapy.
2020-01-23 | GSE144099 | GEO
Project description:Breast cancer cell lines - palmitate vs control
2025-01-23 | E-MTAB-2601 | ExpressionAtlas
Project description:This a model from the article:
A dynamical perspective of CTL cross-priming and regulation: implications for
cancer immunology.
Wodarz D, Jansen VA. Immunol Lett
2003 May 1;86(3):213-27 12706524
,
Abstract:
Cytotoxic T lymphocytes (CTL) responses are required to fight many diseases such
as viral infections and tumors. At the same time, they can cause disease when
induced inappropriately. Which factors regulate CTL and decide whether they
should remain silent or react is open to debate. The phenomenon called
cross-priming has received attention in this respect. That is, CTL expansion
occurs if antigen is recognized on the surface of professional antigen
presenting cells (APCs). This is in contrast to direct presentation where
antigen is seen on the surface of the target cells (e.g. infected cells or tumor
cells). Here we introduce a mathematical model, which takes the phenomenon of
cross-priming into account. We propose a new mechanism of regulation which is
implicit in the dynamics of the CTL: According to the model, the ability of a
CTL response to become established depends on the ratio of cross-presentation to
direct presentation of the antigen. If this ratio is relatively high, CTL
responses are likely to become established. If this ratio is relatively low,
tolerance is the likely outcome. The behavior of the model includes a parameter
region where the outcome depends on the initial conditions. We discuss our
results with respect to the idea of self/non-self discrimination and the danger
signal hypothesis. We apply the model to study the role of CTL in cancer
initiation, cancer evolution/progression, and therapeutic vaccination against
cancers.
This model was taken from the CellML repository
and automatically converted to SBML.
The original model was:
Wodarz D, Jansen VA. (2003) - version=1.0
The original CellML model was created by:
Catherine Lloyd
c.lloyd@auckland.ac.nz
The University of Auckland
This model originates from BioModels Database: A Database of Annotated Published Models (http://www.ebi.ac.uk/biomodels/). It is copyright (c) 2005-2011 The BioModels.net Team.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication
for more information.
In summary, you are entitled to use this encoded model in absolutely any manner you deem suitable, verbatim, or with modification, alone or embedded it in a larger context, redistribute it, commercially or not, in a restricted way or not..
To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92.
2024-09-02 | BIOMD0000000685 | BioModels
Project description:We aimed to investigate the transcriptional memory of metastatic basal-like breast cancer cells by performing nascent RNA-seq by treating with all-trans Retinoic acid (pulse, priming, priming + pulse)
2024-02-02 | GSE211609 | GEO
Project description:Variation in RNA expression in a panel of 30 breast cancer cell lines
2025-01-23 | E-MTAB-4801 | ExpressionAtlas
Project description:Transcription profiling by array of human breast cancer mammospheres and breast tumors
2025-01-24 | E-GEOD-7515 | ExpressionAtlas
Project description:Expression data of ALDH+ breast cancer cells
2025-01-24 | E-GEOD-52327 | ExpressionAtlas
Project description:Expression Analysis of Microdissected Inflammatory Breast Cancer
2025-01-24 | E-GEOD-45581 | ExpressionAtlas
Project description:CAL-51 breast cancer side population cells
2025-01-24 | E-GEOD-18773 | ExpressionAtlas
Project description:Transcription profiling by array of human breast cancer MCF-7 cells treated with novel compound F05 which promotes neurite growth on inhibitory substrates
2025-01-24 | E-GEOD-34331 | ExpressionAtlas